Qualigen therapeutics announces partnership with hande sciences to scale-up manufacturing to support ind-enabling studies for qn-302

Carlsbad, calif., july 06, 2022 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces its partnership with china-based hande sciences (“hande”) to conduct manufacturing scale-up activities to support the company's ind-enabling good laboratory practice (glp) studies for its lead therapeutic program, qn-302.
QLGN Ratings Summary
QLGN Quant Ranking